Hostname: page-component-f554764f5-fr72s Total loading time: 0 Render date: 2025-04-11T09:52:09.132Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of proton-pump inhibitors is associated with depression: a population-based study

Published online by Cambridge University Press:  13 September 2017

Alice Laudisio ,
Raffaele Antonelli Incalzi ,
Antonella Gemma ,
Silvia Giovannini ,
Maria Rita Lo Monaco ,
Davide L. Vetrano ,
Luca Padua ,
Roberto Bernabei  and
Giuseppe Zuccalà
Alice Laudisio*
Affiliation:
Unit of Geriatrics, Department of Medicine, Campus Bio-Medico di Roma University, Rome, Italy
Raffaele Antonelli Incalzi
Affiliation:
Unit of Geriatrics, Department of Medicine, Campus Bio-Medico di Roma University, Rome, Italy
Antonella Gemma
Affiliation:
Department of Homecare Service, Azienda Sanitaria Locale Roma E, Rome, Italy
Silvia Giovannini
Affiliation:
Department of Geriatrics, Neurosciences, and Orthopaedics, Catholic University of Medicine, Rome, Italy
Maria Rita Lo Monaco
Affiliation:
Department of Geriatrics, Neurosciences, and Orthopaedics, Catholic University of Medicine, Rome, Italy
Davide L. Vetrano
Affiliation:
Department of Geriatrics, Neurosciences, and Orthopaedics, Catholic University of Medicine, Rome, Italy
Luca Padua
Affiliation:
Department of Geriatrics, Neurosciences, and Orthopaedics, Catholic University of Medicine, Rome, Italy
Roberto Bernabei
Affiliation:
Department of Geriatrics, Neurosciences, and Orthopaedics, Catholic University of Medicine, Rome, Italy
Giuseppe Zuccalà
Affiliation:
Department of Geriatrics, Neurosciences, and Orthopaedics, Catholic University of Medicine, Rome, Italy
*
Correspondence should be addressed to: Alice Laudisio, Unit of Geriatrics, Department of Medicine, Campus Bio-Medico di Roma University, Via Álvaro del Portillo, 200 - 00128 Rome, Italy. Phone: +39 06225411340. Email: [email protected].
Get access

Abstract

Treatment with proton-pump inhibitors (PPIs) might be associated with neuropsychological side effects. We examined the association between use of PPIs and depressive symptoms in an elderly population. Mood was assessed by the 30-item Geriatric Depression Scale (GDS) in all 344 inhabitants of Tuscania (Italy) aged 75 years and over, without exclusion criteria; depression was defined by a GDS score ≥11. Use of PPIs was associated with a higher GDS score in linear regression analysis (B = 2.43; 95% CI = 0.49–4.38; p = 0.014) after adjusting; also, use of PPIs was associated with increased adjusted probability of depression in logistic regression (OR = 2.38; 95% CI = 1.02–5.58; p = 0.045). Higher PPIs dosages were associated with increased probability of depression (p for trend = 0.014). This association was independent of the diagnosis of peptic disease, as well as the use of antidepressant medications. No association was found between use of H2-blockers or antacids and the GDS score. Calculation of the population attributable risk indicated that 14% of depression cases could be avoided by withdrawal of PPIs. Use of PPIs might represent a frequent cause of depression in older populations; thus, mood should be routinely assessed in elderly patients on PPIs.

Keywords

depressive symptomsproton-pump inhibitorselderlyepidemiology
Type
Brief Report
Information
International Psychogeriatrics , Volume 30 , Issue 1 , January 2018 , pp. 153 - 159
Copyright
Copyright © International Psychogeriatric Association 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Agenzia Italiana del Farmaco (AIFA). (2017). L'uso dei Farmaci in Italia – Rapporto Nazionale gennaio-settembre 2016. Available at: www.agenziafarmaco.gov.it; last accessed June 2017.Google Scholar
Basu, S. and Landis, J. R. (1995). Model-based estimation of population attributable risk under cross-sectional sampling. American Journal of Epidemiology, 142, 1338–1343.CrossRefGoogle ScholarPubMed
Eusebi, L. H. et al. (2017). Proton pump inhibitors: risks of long-term use. last accessed January 2016. doi: 10.1111/jgh.13737.Google Scholar
Gomm, W. et al. (2016). Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurology, 73, 410–416. doi: 10.1001/jamaneurol.2015.4791.Google Scholar
Haastrup, P. F., Rasmussen, S., Hansen, J. M., Christensen, R. D., Søndergaard, J. and Jarbøl, D. E. (2016). General practice variation when initiating long-term prescribing of proton pump inhibitors: a nationwide cohort study. BMC Family Practice, 17, 57. doi: 10.1186/s12875-016-0460-9.Google Scholar
Haenisch, B. et al. (2015). Risk of dementia in elderly patients with the use of proton pump inhibitors. European Archives of Psychiatry and Clinical Neurosciences, 265, 419–428.Google Scholar
Hodkinson, H. M. (1972). Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing, 1, 233–238.Google Scholar
Katz, S., Ford, A. B., Moskowitz, R. W., Jackson, B. A. and Jaffe, M. W. (1963). Studies of illness in the aged: the index of ADL: a standardized measure of biological and psychosocial function. JAMA, 185, 914–919.Google Scholar
Laudisio, A. et al. (2007). Masticatory dysfunction is associated with osteoporosis in older men. Journal of Clinical Periodontology, 34, 964–968. doi: 10.1111/j.1600-051X.2007.01142.x Google Scholar
Lawton, M. P. and Brody, E. M. (1969). Assessment of older: self-maintaining and instrumental activities of daily living. Gerontologist, 9, 179–186.CrossRefGoogle ScholarPubMed
Linder, L., Tamboue, C. and Clements, J. N. (2016). Drug-induced vitamin B12 deficiency: a focus on proton pump inhibitors and histamine-2 antagonists. Journal of Pharmacy Practice, Art no. 0897190016663092. doi: 10.1007/s00406-014-0554-0.Google Scholar
Maggio, M. et al. (2013). Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Internal Medicine, 173, 518–523. doi: 10.1001/jamainternmed.2013.2851.Google Scholar
McCarthy, D. M. (2010). Adverse effects of proton pump inhibitor drugs: clues and conclusions. Current Opinion in Gastroenterology, 26, 624–631. doi: 10.1097/MOG.0b013e32833ea9d9.Google Scholar
Polimeni, G., Cutroneo, P., Gallo, A., Gallo, S., Spina, E. and Caputi, A. P. (2007). Rabeprazole and psychiatric symptoms. Annals of Pharmacotherapy, 41, 1315–1317. doi: 10.1345/aph.1K134.CrossRefGoogle ScholarPubMed
Singh-Manoux, A. et al. (2017). Trajectories of depressive symptoms before diagnosis of dementia: a 28-year follow-up study. JAMA Psychiatry. doi: 10.1001/jamapsychiatry.2017.0660.CrossRefGoogle ScholarPubMed
Vaccaro, R. et al. (2017). Subthreshold depression and clinically significant depression in an Italian population of 70-74-year-olds: prevalence and association with perceptions of self. BioMed Research International. doi: 10.1155/2017/3592359.Google Scholar
Valvassori, S. S. et al. (2010). Effects of a gastrin-releasing peptide receptor antagonist on D-amphetamine-induced oxidative stress in the rat brain. Journal of Neural Transmission (Vienna), 117, 309–316. doi: 10.1007/s00702-010-0373-z.Google Scholar
van der Hoorn, M. M., Tett, S. E., de Vries, O. J., Dobson, A. J. and Peeters, G. M. (2015). The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: a prospective cohort study. Bone, 81, 675–682. doi: 10.1016/j.bone.2015. 08.024.Google Scholar
Vialou, V. et al. (2014). Prefrontal cortical circuit for depression- and anxiety-related behaviors mediated by cholecystokinin: role of ΔFosB. Journal of Neuroscience, 34, 3878–3887. doi: 10.1523/JNEUROSCI.1787- 13.2014.Google Scholar
Washburn, R. A., Smith, K. W., Jette, A. M. and Janney, C. A. (1993). The Physical Activity Scale for the Elderly (PASE): development and evaluation. Journal of Clinical Epidemiology, 46, 153–62.Google Scholar
WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. Available at: http://www.whocc.no/atc_ddd_index/; last accessed 2 February 2017.Google Scholar
World Health Organization. Classification of Diseases (ICD). Available at: http://who.int/classifications/icd/en/; last accessed 2 February 2017.Google Scholar
Yesavage, J. A. et al. (1982-1983). Development and validation of a geriatric depression screening scale: a preliminary report. Journal of Psychiatric Research, 17, 37–49.Google Scholar
Supplementary material: File

Laudisio et al supplementary material

Laudisio et al supplementary material 1

Download Laudisio et al supplementary material(File)
File 86.3 KB
Supplementary material: File

Laudisio et al supplementary material

Laudisio et al supplementary material 2

Download Laudisio et al supplementary material(File)
File 95.3 KB